On 7 September 2026, FIBOCOM (00638.HK) announced the closing of the sale of its aggregate 100% stake in Shanghai Guangyi to Luxshare Precision on 4 September 2026. Post-closing, Shanghai Guangyi is de-consolidated from the company's reporting scope; the company said the transaction is expected to optimize its current-year operating performance and supports its focus on core businesses.
On 7 September 2026, DEEP SOURCE (00990.HK) announced that its AI data center (AIDC) project in Malaysia has been approved by MITI, with certain water and electricity conditions being implemented.
On 7 September 2026, POLY XVERSE IT (00209.HK) announced that Chairman and Executive Director Zhao Kai has resigned, effective 7 September 2026, to focus on other business arrangements, confirming no disagreement with the Board and no matters requiring shareholder or exchange attention.
On 7 September 2026, BIOHEART-B (02185.HK) announced that Giorgio Gobbi, formerly a senior executive at Medtronic and ReCor Medical, has joined subsidiary AngioCare as VP of Global Therapy Development, leading global development of the Iberis® RDN system.
On 8 September 2026, UISEE TECH (01511.HK) announced that its shares have been added to the Stock Connect eligible securities list, effective 7 September 2026, enabling qualified mainland investors to trade through the Stock Connect channel. The company said the inclusion will help broaden its shareholder base and enhance liquidity, as it deepens its global presence in full-scenario L4 autonomous driving.
On 7 September 2026, MAJESTIC DRAGON (00918.HK) announced the appointment of Mr. Zhang Chen as Chief Marketing Officer, effective 7 December 2026.
On 7 September 2026, JIU RONG HOLD (02358.HK) announced that its indirect wholly-owned subsidiary Zhejiang Jiurong Intelligence had received a notice of response from the Qiantang District People's Court of Hangzhou in a housing lease dispute filed by Shuyuan Technology Innovation Development, seeking outstanding rent of RMB 17,056,660.8 plus litigation costs and preservation fees under five lease contracts signed between 2022 and 2025 (with total rent of RMB 17,606,660.8). The hearing is scheduled for 22 October 2026, and the company said the lawsuit may exert pressure on its cash flow and working capital and that it will actively respond while pursuing settlement discussions with creditors.
On 7 September 2026, LONGSYS (09976.HK) published the allotment results for its H-share global offering: the final offer price is HKD 236.00 per share, with trading to commence on 8 September; the Hong Kong public offering was 40.32 times subscribed (36,285 valid applications) and the international offering 3.88 times subscribed (227 placees). The global offering comprised 29,989,450 shares, including 3,911,650 additional shares issued under the offer size adjustment right, generating gross proceeds of approximately HKD 7,077.5 million and net proceeds of approximately HKD 6,803.2 million.
On 7 September 2026, MICOT PHARMA-B (02335.HK) voluntarily announced that its H shares had been included in the eligible share list under the Stock Connect schemes (Shanghai-Hong Kong and Shenzhen-Hong Kong), effective from the same day, pursuant to the announcements of the two exchanges. Eligible mainland investors will be able to trade the company's shares through the two exchanges.
On 7 September 2026, LONGBIO-B (01779.HK) voluntarily announced that it had been included in the eligible securities lists under the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect schemes, effective from the same day, pursuant to the notices issued by the Shanghai and Shenzhen stock exchanges. Eligible mainland investors will be able to trade the company's shares directly through the two exchanges, and the company expects the inclusion to broaden its shareholder base and improve share liquidity.
On 7 September 2026, LONGFOR GROUP (00960.HK) announced its unaudited operational data for August 2026: contracted sales of RMB 2.20 billion with contracted sales area of 250,000 sq.m. in the month (RMB 1.50 billion attributable to shareholders' interests), and cumulative total contracted sales of RMB 20.84 billion with contracted sales area of 2,239,000 sq.m. for the eight months ended 31 August 2026, together with operations and services revenue (exclusive of tax) of approximately RMB 18.18 billion over the same period.
On 7 September 2026, ESTUN (02715.HK) announced the completion of its acquisition of 100% equity in Estun Kuzhuo on 2 September 2026 in accordance with the acquisition agreement, making it an indirect wholly-owned subsidiary consolidated into the group's financial statements. The cash acquisition, with a total consideration of RMB 487.10 million, was approved by the board and the extraordinary shareholders' meeting and constitutes a connected transaction.
On 7 September 2026, MINIEYE (02431.HK) voluntarily announced that chairman, executive director and general manager Dr. Liu Guoqing had purchased 100,000 H shares on the open market at an average price of approximately HKD 2.3835 per share, representing approximately 0.02% of the issued shares. Following the purchase, his beneficial holdings increased to 34,583,503 shares (approximately 7.8%), with aggregate holdings of approximately 17.55% together with his concert parties.
On 7 September 2026, CICC (03908.HK) announced that the CSRC had issued an approval (Zhengjian Xuke [2026] No. 2377) approving and consenting to the registration of its merger by absorption of Dongxing Securities and Cinda Securities together with related shareholding changes, satisfying the CSRC approval condition for the merger agreement. The company also set out its cash election arrangements: with the 2025 final dividend paid, the cash prices have been adjusted to RMB 34.57 per A share and HKD 18.60 per H share, and the H-share election period runs from 15 to 17 September (closing 4:30 p.m. on 17 September). CICC H shares closed at HKD 21.90 on 4 September, a premium of about 17.74% over the exercise price, and exercising the election may result in losses.
On 7 September 2026, VIVA GOODS (00933.HK) announced that its wholly-owned subsidiary had further acquired 19,231,000 shares in Li Ning (02331.HK) on the open market through the Stock Exchange for a total consideration of approximately HKD 263,736,000 (approximately HKD 13.71 per share), raising its stake from approximately 18.30% to 19.04%. As two applicable percentage ratios exceed 5% but remain below 25%, the acquisition constitutes a discloseable transaction, while the company's two earlier rounds of acquisitions were each classified as major transactions.
On 7 September 2026, UNITED LAB (03933.HK) voluntarily announced that UBT251 injection, a Class 1 innovative drug developed by its wholly-owned subsidiary United Bio-Tech, had completed first participant dosing in the Phase III clinical study for type 2 diabetes in China, which comprises UNIGUIDE-1 (360 participants, placebo-controlled) and UNIGUIDE-2 (956 participants, semaglutide-controlled). UBT251 is a long-acting GLP-1/GIP/GCG triple receptor agonist; the company is the first in China and the second globally to obtain clinical approval for such an agonist prepared by chemical synthesis of peptides, and entered into an exclusive license agreement with Novo Nordisk in March 2025.
